Prabal Banerjee News Today

Mergers and acquisitions (M&As) in India have moved into the slow lane, dropping 43 per cent in terms of deal value to touch $13.37 billion since January this year to date, compared to the same period in the last year. According to data sourced from Bloomberg, Indian companies reported deal value worth $23.5 billion between January and March 22, 2023. Data Infrastructure Trusts acquisition of American Tower Corporations India telecom towers business for $2.5 billion was the top deal for the ongo...

Blockchain start-up Avail raised $27 million in funding led by Peter Thiels Founders Fund and Dragonfly Capital. The funds will be used for product development, hiring, and marketing. Franklin Templeton launched a blockchain mutual fund. Regulatory approval for spot bitcoin ETFs could bring more awareness to the industry.

Foreign banks and private credit funds are queuing up to fund acquisitions by Indian companies who are buying out their local rivals. The Adani Group, Torrent Group, and the Hindujas have approached several foreign banks and private equity (PE) firms to fund their acquisitions. Global investors have about $2 trillion of funds to invest, and about $100 to $150 billion is set aside for India, according to an estimate by JP Morgan.

Several companies, led by Reliance Industries, raised funds from overseas

Ethereum scaling project Polygon has bid adieu to research lead Prabal Banerjee as he joins its spin-off Avail, a modular blockchain project. Banerjee has…

Genesis Drug Discovery and Development Acquires Integrated Analytical Solutions to Add "Off the Shelf" PK Profiling Capabilities to Its Portfolio News provided by Share this article ® (GBG) and its Contract Research Organization (CRO) arm Genesis Drug Discovery & Development™ (GD 3) announced today that it has acquired the Berkeley-based CRO Integrated Analytical Solutions (IAS). Founded in 2004 and located in the San Francisco bay area, IAS is a GxP-compliant CRO providing bioanalytical, dr...

Genesis Drug Discovery and Development Expands Its Presence in the Clinical Space by Acquiring STATKING Clinical Services News provided by Share this article ® (GBG) and its Contract Research Organization (CRO) arm Genesis Drug Discovery & Development™ (GD 3) announced today that it has acquired the Cincinnati-based CRO STATKING Clinical Services. Established in 1989, STATKING provides clinical trial services, including clinical trial management, protocol development, biostatistics, clinical...